HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer
Condition: Prostate Cancer Intervention: Radiation: HDR brachytherapy as monotherapy Sponsor: CR-CSSS Champlain-Charles-Le Moyne Recruiting
Conclusions: The use of a hydrogel prior to salvage HDR-BT in a patient previously treated with HDR-BT is feasible and could help reduce the rectal exposure in the salvage setting. PMID: 29789766 [PubMed]
Conclusions: LDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients. PMID: 29789764 [PubMed]
We describe the PROstate Multicentre External beam radioTHErapy Using Stereotactic boost (PROMETHEUS) study. ...
CONCLUSION: HDR-BRT with supplemental EBRT results in low biochemical relapse-free survival rates associated with a very low incidence of higher-grade late adverse events. PMID: 29764692 [PubMed - as supplied by publisher]
To report the clinical outcomes and treatment-related toxicities after combined high-dose-rate (HDR) brachytherapy (BRT) with external beam radiotherapy (EBRT) for patients with clinically localised high-risk prostate cancer.
Authors: Persaud S, Persaud M, Goetz L, Narinesingh D Abstract Prostate cancer mortality in the Caribbean region is among the highest in the world and prostate cancer is the most common cancer in Trinidad and Tobago. There is a two-tiered healthcare system in Trinidad and Tobago, and prostate cancer related issues account for a significant percentage of urologists' workload. Delivery of care is sometimes constrained by limited financial resources. Prostate-specific antigen testing is widely available but there is no national guideline. Treatment options available include active surveillance, radical prostatectomy, ...
BJU International, EarlyView.
In this study we aimed to examine long-term biochemical control and survival with low-dose-rate brachytherapy (LDR-BT) alone for HRPC.
Prostate cancer (CaP) is characterized by a low a/b ratio relative to surrounding normal tissue, and consequently a therapeutic gain could be achieved with dose escalation. While potentially ablative PSA nadirs have been demonstrated following LDR brachytherapy, the ability to achieve ablation following stereotactic body radiation therapy (SBRT) remains unclear. The purpose of this study was to report the clinical outcomes, PSA kinetics, and toxicities in patients with low and intermediate-risk CaP treated on a prospective, Phase I/II, IRB approved dose-escalated SBRT trial.
High dose rate (HDR) brachytherapy as monotherapy has been recently established as a treatment modality for low- and/or intermediate-risk prostate cancer (LIR-PC); however, clinical results of this technique remain limited. Here we describe our institutional HDR monotherapy experience and report early clinical outcomes.